Literature DB >> 12057142

Extensive stage small cell lung cancer.

H B Niell1.   

Abstract

Small cell lung cancer is a rapidly proliferating, biologically aggressive form of lung cancer that has a short survival without treatment. Chemotherapy is the foundation of the therapeutic approach to patients with small cell lung cancer. Most patients present with extensive disease, and, although few patients are cured, significant improvement in survival is possible with modern chemotherapy. The role of radiation therapy in extensive disease is palliative, and surgery has little role in patient management. The standard chemotherapy regimen for patients with small cell lung cancer has become either cisplatin or carboplatin with etoposide. Second-line chemotherapy regimens are moderately effective in patients previously responding to initial chemotherapy. Newer chemotherapy agents show promise, but few randomized trials have been completed in extensive disease. Physicians should be encouraged to include their patients with extensive small cell lung cancer in the evolving clinical trials.

Entities:  

Mesh:

Year:  2001        PMID: 12057142     DOI: 10.1007/s11864-001-0018-4

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  40 in total

1.  Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.

Authors:  F A Shepherd; W K Evans; R MacCormick; R Feld; J C Yau
Journal:  Cancer Treat Rep       Date:  1987-10

2.  Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.

Authors:  D H Johnson; F A Greco; J Strupp; K R Hande; J D Hainsworth
Journal:  J Clin Oncol       Date:  1990-10       Impact factor: 44.544

3.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

Review 4.  Recent developments in chemotherapy treatment of small-cell lung cancer.

Authors:  D H Johnson
Journal:  Semin Oncol       Date:  1993-08       Impact factor: 4.929

5.  Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.

Authors:  G Batist; D N Carney; K H Cowan; S R Veach; M Gilliom; P A Bunn; D C Ihde
Journal:  J Clin Oncol       Date:  1986-06       Impact factor: 44.544

6.  Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.

Authors:  D S Ettinger; D M Finkelstein; R P Sarma; D H Johnson
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

7.  cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Authors:  F M Schabel; M W Trader; W R Laster; T H Corbett; D P Griswold
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

8.  Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.

Authors:  P A Kosmidis; E Samantas; G Fountzilas; N Pavlidis; F Apostolopoulou; D Skarlos
Journal:  Semin Oncol       Date:  1994-06       Impact factor: 4.929

9.  CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

Authors:  N Masuda; M Fukuoka; Y Kusunoki; K Matsui; N Takifuji; S Kudoh; S Negoro; M Nishioka; K Nakagawa; M Takada
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

10.  Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

View more
  2 in total

1.  Nicotine enhances the antiapoptotic function of Mcl-1 through phosphorylation.

Authors:  Jinfeng Zhao; Meiguo Xin; Ton Wang; Yangde Zhang; Xingming Deng
Journal:  Mol Cancer Res       Date:  2009-11-10       Impact factor: 5.852

2.  Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.

Authors:  Ravi Salgia; R Waide Weaver; Michael McCleod; John R Stille; S Betty Yan; Stephanie Roberson; John Polzer; Amy Flynt; Eyas Raddad; Victoria L Peek; Sameera R Wijayawardana; Suzane L Um; Steve Gross; Mark C Connelly; Carrie Morano; Madeline Repollet; Renouard Sanders; Kurt Baeten; David D'Haese; David R Spigel
Journal:  Invest New Drugs       Date:  2017-03-15       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.